维普期刊资源整合服务平台（V6.5）

24篇 您的检索式：作者名="la ROSEE P"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Characterization of thymic atrophy and the mechanism of thymocyte depletion after in vivo exposure to a mixture of herbrcides 显示文摘	De la Rose P Barnett JB Schafer R	2005	J toxicol Environ Health A2005，68，2：	1
2	Thrombus formation after transcatheter closure of atrial septal defect显示文摘	La Rosee K Deutsch H J Schnabel P	1999	Am J Cardiol1999，84，：	1
3	显示文摘	La Rosee P Johnson K O' Dwyer ME	2002	Exp Hematol2002，30，7：	1
4	Imatinib therapy in chronic myelogenous leukemia:strategies to avoid and overcome resistance显示文摘	Hochhaus A La Rosee P	2004	Leukemia2004，18，：	1
5	In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia 显示文摘	La Rosee P Johnson K O'Dwyer ME	2002	Exp Hematol2002，30，7：	1
6	Effects of M LN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis显示文摘	GRISWOLD I J SHEN L J LA ROSEE P	2004	Blood2004，104，9：	1
7	Insights from pre-clinical studies for new combination treatment regimens with the Ber-Abl kinse inhibitor imatinib mesylate (Gleevec/Glivec)in chronic myelogenous leukemia:a translational perspective显示文摘	La Rosee P O' Dwyer ME Druker BJ		0，，：	1
8	In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia 显示文摘	La Rosee P Johnson K O Dwyer ME	2002	Exp Hematol2002，30，7：	1
9	Resistance to imatiminib: mu- tations and beyond显示文摘	LA ROSEE P DEININGER M W	2010	Semin Hametol2010，47，4：	1
10	显示文摘	La Rosee P O' Dwyer ME Druker BJ	2002	Leukemia2002，16，7：	1
11	Nm23 nucleoside diphosphate kinase: toward a structural and biochemical understanding of its biological functions显示文摘	De La Rose A Williams R L Steeg P S	1995	BioEssays1995，17，1：	1
12	Effects of MLN518, a dual FLT3 and KIT inhibitor,on normal and malignant hematopoiesis 显示文摘	GRISWOLD IJ SHEN LJ la ROSEE P	2004	Blood2004，104，9：	1
13	Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase 显示文摘	Kantarjian HM Cortes J La Rosee P	2010	Cancer2010，116，6：	1
14	Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resist- ance remain sensitive toimatinib 显示文摘	Corbin AS La Rosee P Stoffregen EP	2003	Blood2003，101，11：	1
15	Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis显示文摘	Griswold IJ Shen LJ La Rosee P	2004	Blood2004，104，9：	1
16	显示文摘	Hochhaus A Weisser A La Rosee P	2000	Leukemia2000，14，：	1
17	Characterization of thymic atrophy and the mechanism of thymocyte depletion after in vlvo exposure to a mixture of herbicides显示文摘	de la Rose P Barnett J B Schafer R	2005	J Toxi col Environ Health A2005，68，2：	1
18	Thrombus formation after transcatheterclosure of atrial septal defect显示文摘	LA ROSEE K DEUTSCH H J SCHNABEL P	1999	Am J Cardiol1999，84，3：	1
19	In vitro studies of the combination of imatinib mesylate (Gleevec)> and arsenic trioxide (Trisenox) in chronic myelogenous leukemia显示文摘	La Rosee P Johnson K O'Dwyer M E	2002	Exp Hematol2002，30，：	1
20	显示文摘	La Rosee P Corbin AS Stoffregen EP	2002	Cancer Res2002，62，24：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示